ARWR Latest Headlines

Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026

at www.tipranks.com (Sat, 7-Feb 7:16 PM)

Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)

at www.tipranks.com (Fri, 6-Feb 8:01 AM)

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Illumina (ILMN) and Rigel (RIGL)

at www.tipranks.com (Fri, 6-Feb 7:20 AM)

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Resmed (RMD) and Bristol-Myers Squibb (BMY)

at www.tipranks.com (Fri, 6-Feb 6:50 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Ocular Therapeutix (OCUL) and Arrowhead Pharmaceuticals (ARWR)

at www.tipranks.com (Fri, 6-Feb 6:40 AM)

Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline

at seekingalpha.com (Fri, 6-Feb 12:35 AM)

Arrowhead Pharmaceuticals to Join S&P MidCap 400: What the Index Shift Means for ARWR

Market Chameleon (Thu, 5-Feb 8:40 AM)

Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis

at www.tipranks.com (Thu, 5-Feb 8:15 PM)

Arrowhead Pharmaceuticals GAAP EPS of $0.22 beats by $0.37, revenue of $264.03M beats by $33.18M

at seekingalpha.com (Thu, 5-Feb 4:24 PM)

Here are the major earnings after the close Thursday

at seekingalpha.com (Thu, 5-Feb 10:00 AM)

Arrowhead Pharmaceuticals Q1 2026 Earnings Preview

at seekingalpha.com (Wed, 4-Feb 5:35 PM)

Arrowhead Pharmaceuticals Raises $625M in Convertible Notes and Upsizes Offerings: What Does This Mean for Investors?

Market Chameleon (Thu, 8-Jan 9:33 AM)

Arrowhead’s REDEMPLO Wins Health Canada Approval—A Potential Breakthrough for Rare Lipid Disorder Patients

Market Chameleon (Tue, 6-Jan 11:07 AM)

ARWR Trial Data Shows ARO-INHBE Combination Doubles Weight Loss and Triples Fat Reduction in Obese Diabetics

Market Chameleon (Tue, 6-Jan 7:51 AM)

Arrowhead's Novel RNAi Therapy Targets Alzheimer's at the Genetic Level—Phase 1/2a Study Kicks Off

Market Chameleon (Mon, 8-Dec 7:58 AM)

FDA Breakthrough Therapy Designation for Plozasiran Highlights Arrowhead’s Innovative Approach to Severe Hypertriglyceridemia

Market Chameleon (Tue, 2-Dec 8:36 AM)

FDA Approval and Financial Turnaround Highlight Arrowhead Pharmaceuticals’ Breakout Year

Market Chameleon (Wed, 26-Nov 11:45 AM)